Tretinoin Capsules Rx
Generic Name and Formulations:
Tretinoin 10mg; soft gelatin caps; contain parabens.
Various generic manufacturers
Indications for Tretinoin Capsules:
Induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARα gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline-based chemotherapy is contraindicated.
Use only for induction of remission. 45mg/m2 per day in two divided doses until complete remission is documented. Discontinue 30 days after complete remission or after 90 days of treatment, whichever occurs first.
See full labeling.
Experienced physician and institution. Retinoic Acid-APl syndrome. Leukocytosis at presentation and rapidly evolving leukocytosis during tretinoin treatment. Teratogenic effects.
Confirm APL diagnosis. Monitor for Retinoic Acid-APL (RA-APL) syndrome, leukocytosis, pseudotumor cerebri, or respiratory compromise. Consider temporarily interrupting therapy if moderate to severe RA-APL syndrome develops. Monitor blood counts, coagulation profile, lipids, liver function; consider temporary withdrawal if tests >5XULN. Pregnancy (Cat.D); obtain negative pregnancy test 1 week before starting treatment, counsel patient about need to use 2 effective methods of contraception during, and 1 month after therapy. Nursing mothers: not recommended.
Do not administer with Vitamin A. May be potentiated or antagonized by CYP450 enzyme inducers or inhibitors. Caution with anti-fibrinolytic agents; and other agents known to cause pseudotumor cerebri/intracranial hypertension.
Headache, fever, skin/mucous membrane dryness, bone pain, GI upset, rash, mucositis, pruritus, increased sweating, visual disturbances, alopecia; RA-APL syndrome, leukocytosis, pseudotumor cerebri, hypercholesterolemia/hypertriglyceridemia, others.
Formerly known under the brand name Vesanoid.
Neurology Advisor Articles
- Ajovy Injection Approved for Migraine Prevention in Adults
- Few With Acute Migraine Take Triptans, Many Discontinue the Drug
- Natalizumab Improves Cognitive Function in Multiple Sclerosis
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Multiple Sclerosis Increases Risk for Infection During Pregnancy
- Magnesium Has No Effect on Cognitive Outcomes Following Aneurysmal Subarachnoid Hemorrhage
- Incorporating Guidelines Into Clinical Practice: An Interview With Gary L. LeRoy, MD
- Combo Physical, Mental Activity Prevents Cognitive Decline
- Medicaid Expansion Linked to Gains in Insurance Coverage